| Literature DB >> 32378520 |
Kanako Ishihara1, Chihiro Sunagawa1, Takashi Haneishi2,3, Naoko Miyaguchi1, Natsumi Endo3, Tomomi Tanaka3.
Abstract
To evaluate the effect of antimicrobial susceptibility on outcomes, we compared the minimum inhibitory concentrations (MICs) for Staphylococcus, Streptococcus, and the family Enterobacteriaceae from cured and uncured mastitis cases; milk shipment for uncured cases could not be resumed within 3 weeks after initial clinical examination. A higher MIC50 of ampicillin and a higher MIC90 of cefazolin for Enterobacteriaceae isolates were observed for cured rather than uncured cases with differences in ≥2 tubes. Endotoxins are generally released from Enterobacteriaceae upon antimicrobial treatment; their amounts are presumed to be greater in mastitis cases resulting from β-lactam antibiotic-susceptible rather than -resistant microbes. For staphylococcal and streptococcal isolates, the MIC50 and MIC90 of β-lactam antibiotics were similar for cured and uncured cases.Entities:
Keywords: antimicrobial resistance; mastitis
Mesh:
Substances:
Year: 2020 PMID: 32378520 PMCID: PMC7399304 DOI: 10.1292/jvms.19-0692
Source DB: PubMed Journal: J Vet Med Sci ISSN: 0916-7250 Impact factor: 1.267
Comparison of minimum inhibitory concentration (µg/ml) for causative bacteria by outcome (cured and uncured cases)
| Antimicrobials | Cured1) | Uncured | Difference | ||
|---|---|---|---|---|---|
| (a) | (b) | [log2 (b/a)] | |||
| Ampicillin | |||||
| MIC50 | 0.25 | 0.5 | 1 | ||
| MIC90 | 2 | 2 | 0 | ||
| MIC50 | 0.12 | 0.12 | 0 | ||
| MIC90 | 0.5 | 0.5 | 0 | ||
| MIC50 | |||||
| MIC90 | >128 | >128 | NA | ||
| MIC50 | |||||
| MIC90 | >128 | >128 | NA | ||
| Cefazolin | |||||
| MIC50 | 0.5 | 0.5 | 0 | ||
| MIC90 | 1 | 1 | 0 | ||
| MIC50 | 0.25 | 0.5 | 1 | ||
| MIC90 | 0.5 | 1 | 1 | ||
| MIC50 | 2 | 1 | –1 | ||
| MIC90 | |||||
| MIC50 | 2 | 1 | –1 | ||
| MIC90 | >64 | >64 | NA | ||
1) Cases wherein milk shipment was resumed within 3 weeks were defined as cured cases. 2) The data of Enterobacteriaceae (n=41) includes the data of Escherichia coli (n=34). NA, no application; MIC, minimum inhibitory concentration. Underlined, MIC of isolates from cured cases was higher than those from uncured cases with a difference of ≥2 tubes.
Antimicrobial resistance patterns for Staphylococcus spp. isolated from mastitis samples
| Antimicrobial resistance pattern | Subtotal | |
|---|---|---|
| PC-ABPC-CPDX-EM | 1 | |
| PC-ABPC-CEZ | 1 | 1 |
| PC-ABPC-CPDX | 1 | |
| PC-ABPC-EM | 1 | 1 |
| PC-ABPC-OFLX | 1 | 1 |
| CPDX-EM | 1 | |
| PC-ABPC | 19 | 15 |
| PC-CPDX | 1 | |
| ABPC | 2 | 2 |
| OFLX | 1 | 1 |
| Susceptible | 35 | 13 |
| Total | 64 | 34 |
PC, penicillin (breakpoint, 0.25 µg/ml); ABPC, ampicillin (0.5 µg/ml); CEZ, cefazolin (32 µg/ml); CPDX, cefpodoxime (4 µg/ml); EM, erythromycin (8 µg/ml); OFLX, ofloxacin (4 µg/ml).
Antimicrobial resistance patterns for Streptococcus spp. isolated from mastitis samples
| Antimicrobial resistance pattern | Subtotal | ||
|---|---|---|---|
| PC-ABPC-KM-TC | 1 | ||
| PC-KM-EM-TC | 1 | 1 | |
| KM-EM-TC | 2 | 2 | |
| PC-KM-TC | 4 | 4 | |
| PC-EM-TC | 3 | 3 | |
| EM-TC | 6 | 5 | |
| KM-OFLX | 1 | ||
| KM-TC | 10 | 7 | 2 |
| PC-ABPC | 1 | 1 | |
| PC-KM | 3 | 2 | |
| PC-TC | 1 | 1 | |
| KM | 21 | 1 | 3 |
| PC | 2 | 1 | 1 |
| TC | 4 | 2 | 2 |
| Susceptible | 10 | 8 | 1 |
| Total | 70 | 20 | 27 |
PC, penicillin (breakpoint, 0.25 µg/ml); ABPC, ampicillin (8 µg/ml); CEZ, cefazolin (32 µg/ml); CPDX, cefpodoxime (8 µg/ml); EM, erythromycin (1 µg/ml); OFLX, ofloxacin (8 µg/ml).
Antimicrobial resistance patterns for family Enterobacteriaceae isolated from mastitis samples
| Antimicrobial resistance pattern | Subtotal | |
|---|---|---|
| ABPC-CEZ-CPDX-ACV-CPDX/CVA-KM-TC-CP-ST | 1 | 1 |
| ABPC-CEZ-CPDX-ACV-CPDX/CVA-KM-TC-ST | 1 | 1 |
| ABPC-CEZ-CPDX-TC-CP-CL-NA-CPFX | 1 | 1 |
| ABPC-CEZ-ACV-TC-CL | 1 | |
| ABPC-CEZ-CPDX-TC-CL | 1 | 1 |
| ABPC-TC-NA-ST | 1 | 1 |
| ABPC-KM-TC-ST | 1 | 1 |
| ABPC-CEZ-ACV | 2 | |
| ABPC-TC-CL | 2 | 2 |
| ABPC-TC-CP | 1 | 1 |
| ABPC-TC-ST | 3 | 3 |
| ABPC-TC | 3 | 3 |
| TC-CL | 1 | 1 |
| ABPC | 6 | 2 |
| CL | 2 | 2 |
| TC | 3 | 3 |
| Susceptible | 14 | 13 |
| Total | 44 | 36 |
ABPC, ampicillin (breakpoint, 32 µg/ml); CEZ, cefazolin (8 µg/ml); CPDX, cefpodoxime (8 µg/ml); ACV, amoxicillin/clavulanic acid (32/16 µg/ml); CPDX/CVA, cefpodoxime/clavulanic acid (32/4 µg/ml); KM, kanamycin (64 µg/ml); TC, tetracycline (16 µg/ml); CP, chloramphenicol (32 µg/ml); CL, colistin (4 µg/ml); NA, nalidixic acid (32 µg/ml); CPFX, ciprofloxacin (4 µg/ml).